Evotec Expands Compound Management Capability to East Coast of the United States

Evotec Expands Compound Management Capability to East Coast of the United
States

HAMBURG, Germany, April 29, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) (ISIN:DE0005664809) today announced that Evotec (US) Inc. has
executed a multi-year lease on a facility specifically designed to expand the
offering of its Compound Management Services on the East Coast of the United
States.

The facility, located in Branford Connecticut, is strategically positioned to
support the strong presence of Evotec's drug discovery collaborators along the
East Coast of the United States. The new facility will be modern, cost
effective and scalable for continued growth. The investment into industry
leading technologies, specifically aimed at library management, and the access
to incremental space will enable Evotec to better support the East Coast
pharmaceutical and biopharmaceutical industry for the coming years. The
facility will be fully operational early Q3 2013 and will complement the
existing facility in South San Francisco which will continue to be fully
operational and serve existing clients.

Scott Snyder, Executive Vice President Compound Management of Evotec,
commented: "This is an important strategic expansion of our EVT Execute
compound management offering which Evotec first acquired in South San
Francisco in 2011. The significant investment will enable Evotec to better
compete for East Coast compound management opportunities and continue to
provide the very best services and solutions to our partners."

About Evotec AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
with Janssen Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Gabriele Hansen
         Head of Corporate Communications
         +49.(0)40.560 81-255
         +49.(0)40.560 81-222 Fax
         gabriele.hansen@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)